Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “FGFR2 Amplification”

19 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 19 of 19 results

Not applicableStudy completedNCT02450136
What this trial is testing

Single-arm Study to Evaluate the Safety and Efficacy of Pazopanib, in Subjects With FGFR2 Amplification, FGFR2 Mutation Refractory Solid Tumors

Who this might be right for
Refractory Solid Tumors
Samsung Medical Center 2
Testing effectiveness (Phase 2)Study completedNCT03230318
What this trial is testing

Derazantinib in Subjects With FGFR2 Gene Fusion-, Mutation- or Amplification- Positive Inoperable or Advanced Intrahepatic Cholangiocarcinoma

Who this might be right for
Intrahepatic CholangiocarcinomaCombined Hepatocellular and Cholangiocarcinoma
Basilea Pharmaceutica 148
Testing effectiveness (Phase 2)UnknownNCT04096417
What this trial is testing

Pemigatinib for the Treatment of Metastatic or Unresectable Colorectal Cancer Harboring FGFR Alterations

Who this might be right for
FGFR1 Gene AmplificationFGFR1 Gene MutationFGFR1 Gene Translocation+16 more
Academic and Community Cancer Research United 14
Testing effectiveness (Phase 2)UnknownNCT06022289
What this trial is testing

Pemigatinib for FGF/FGFR Alterations Advanced Pan Solid Tumors

Who this might be right for
Solid TumorFGF Receptor Gene MutationFGF Amplification+2 more
Tianjin Medical University Second Hospital 20
Early research (Phase 1)Looking for participantsNCT06160752
What this trial is testing

Safety and Anti-Tumor Activity of TYRA-200 in Advanced Cholangiocarcinoma With Activating FGFR2 Gene Alterations

Who this might be right for
Locally Advanced CholangiocarcinomaIntrahepatic CholangiocarcinomaSolid Tumor+1 more
Tyra Biosciences, Inc 40
Not applicableStudy completedNCT02450123
What this trial is testing

Single-arm Study to Evaluate the Safety and Efficacy of Sunitinib, in Subjects With RET Fusion Positive or FGFR2 Amplification, Refractory Solid Tumors

Who this might be right for
Refractory Solid Tumors
Samsung Medical Center 1
Early research (Phase 1)Study completedNCT01004224
What this trial is testing

A Dose Escalation Study in Adult Patients With Advanced Solid Malignancies

Who this might be right for
Advanced Solid Tumors With Alterations of FGFR1, 2 and or 3Squamous Lung Cancer With FGFR1 AmplificationBladder Cancer With FGFR3 Mutation or Fusion+3 more
Novartis Pharmaceuticals 208
Testing effectiveness (Phase 2)Study completedNCT01719549
What this trial is testing

Dovitinib for Gastric Cancer With FGFR2 Amplification: GASDOVI-1

Who this might be right for
Gastric Cancer
Asan Medical Center 19
Testing effectiveness (Phase 2)UnknownNCT05859477
What this trial is testing

Nivolumab in Combination With Chemotherapy for FGFR2-positive Metastatic Gastric Cancer

Who this might be right for
Metastatic Gastric CancerPD-L1 Gene AmplificationFGFR2 Amplification
Kidney Cancer Research Bureau 23
Testing effectiveness (Phase 2)Active Not RecruitingNCT04526106
What this trial is testing

REFOCUS: A First-in-Human Study of Highly Selective FGFR2 Inhibitor, RLY-4008, in Patients With ICC and Other Advanced Solid Tumors

Who this might be right for
FGFR2 AmplificationFGFR2 Gene MutationFGFR2 Gene Fusion/Rearrangement+5 more
Elevar Therapeutics 490
Testing effectiveness (Phase 2)Ended earlyNCT06206278
What this trial is testing

Evaluation of Infigratinib in Patients With Locally Advanced or Metastatic Gastric Cancer or GEJ Adenocarcinoma

Who this might be right for
Gastric CancerGastroesophageal Junction Adenocarcinoma
LianBio LLC 6
Early research (Phase 1)WithdrawnNCT05510427
What this trial is testing

Phase Ib Trial of Infigratinib In Combination With Atezolizumab And Bevacizumab for The Second-Line Treatment of Advanced Cholangiocarcinoma With FGFR2 Fusion/Amplification

Who this might be right for
CholangiocarcinomaLiver Cancer
M.D. Anderson Cancer Center
Testing effectiveness (Phase 2)Ended earlyNCT04024436
What this trial is testing

TAS-120 in Patients With Metastatic Breast Cancer

Who this might be right for
Metastatic Breast CancerFGFR 1 High AmplificationFGFR2 Amplification
Taiho Oncology, Inc. 64
Testing effectiveness (Phase 2)Ended earlyNCT01457846
What this trial is testing

Efficacy and Safety of AZD4547 Versus Paclitaxel in Patients With Advanced Gastric or Gastro-oesophageal Cancer

Who this might be right for
Gastro-oesophageal Junction CancerGastric Cancer
AstraZeneca 960
Testing effectiveness (Phase 2)UnknownNCT05019794
What this trial is testing

Infigratinib in Subjects With GC or GEJ With FGFR2 Amplification or Other Solid Tumors With Other FGFR Alterations

Who this might be right for
Gastric CancerGastroesophageal Junction AdenocarcinomaSolid Tumor
LianBio LLC 80
Not applicableEnded earlyNCT05052372
What this trial is testing

Biomarker Research Study for Patients With FGFR-Mutant Bladder Cancer Receiving Erdafitinib

Who this might be right for
Bladder CancerUrothelial CarcinomaTransitional Cell Carcinoma+10 more
xCures 2
Testing effectiveness (Phase 2)Looking for participantsNCT06777316
What this trial is testing

An FGFR2/3 Inhibitor (CGT4859) in Patients With Cholangiocarcinoma and Other Advanced Solid Tumors

Who this might be right for
Intrahepatic Cholangiocarcinoma (Icc)CholangiocarcinomaOther Solid Tumors, Adult+9 more
Cogent Biosciences, Inc. 110
Large-scale testing (Phase 3)Study completedNCT02965378
What this trial is testing

Lung-MAP: AZD4547 as Second-Line Therapy in Treating FGFR Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer

Who this might be right for
FGFR1 Gene AmplificationFGFR1 Gene MutationFGFR2 Gene Amplification+5 more
SWOG Cancer Research Network 43
Testing effectiveness (Phase 2)Ended earlyNCT02706691
What this trial is testing

BGJ398 in Treating Patients With FGFR Positive Recurrent Head and Neck Cancer

Who this might be right for
FGFR Gene AmplificationFGFR1 Gene AmplificationFGFR2 Gene Amplification+7 more
University of Chicago 1